Trial Profile
REbiSmartTM Retrospective ADherencE Review (READER) An Observational, Retrospective, UK & Ireland Audit of Patient Adherence to Rebif(R) Injections Using the RebiSmartTM Injection Device
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 11 Dec 2018
Price :
$35
*
At a glance
- Drugs Interferon beta-1a (Primary)
- Indications Multiple sclerosis
- Focus Therapeutic Use
- Acronyms READER
- Sponsors Merck KGaA
- 30 Sep 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 20 Sep 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.
- 23 May 2012 New trial record